Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

Seligmann, Jenny F; Elliott, Faye; Richman, Susan D; Jacobs, Bart; Hemmings, Gemma; Brown, Sarah; Barrett, Jennifer H; Tejpar, Sabine; Quirke, Philip; Seymour, Matthew T.
JAMA Oncol; 2016 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-26867820

Não foram localizados documentos relacionados